In a xenograft mice with cytokine receptor 2 (CRLF2)/JAK Ph-like ALL mutations, Gedatolisib therapy reduced the viability of ALL cells by 92.2%. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.